American Association for Cancer Research

SU2C-St. Baldrick's Joint Scientific Advisory Committee

The Joint Scientific Advisory Committee for the SU2C-St. Baldrick's Pediatric Dream Team Translational Cancer Research Grant is dedicated to seeking out the most innovative and promising pediatric oncology research projects. The committee is comprised of highly accomplished senior laboratory researchers and physician-scientists, as well as advocates. The scientific oversight provided by the Joint Scientific Advisory Committee is critical to achieve Stand Up To Cancer's mission to translate the most promising cancer research into real advances in cancer diagnosis, treatment and prevention as quickly as possible.



Joint Scientific Advisory Committee Biographies

 

Phillip A. Sharp, Chairperson Steven J. Burakoff
Lee J. Helman, Vice-chairperson      Alan D. D'Andrea
Jeffrey M. Lipton, Vice-chairperson Stephen H. Friend
Julian Adams Michael B. Kastan
Peter C. Adamson Paul S. Meltzer
Kenneth C. Anderson Geoffrey Corb
Smita Bhatia Nancy F. Goodman

 


Phillip A. Sharp, Ph.D., Chairperson
Institute Professor
David H. Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA


A world leader of research in molecular biology and biochemistry, Dr. Phillip A. Sharp is institute professor at the Massachusetts Institute of Technology's David H. Koch Institute for Integrative Cancer Research. Dr. Sharp earned a B.A. degree from Union College, KY, in 1966, and a Ph.D. in chemistry from the University of Illinois, Champaign-Urbana, in 1969. He did his postdoctoral training at the California Institute of Technology, where he studied the molecular biology of plasmids, and then studied gene expression in human cells at the Cold Spring Harbor Laboratory under James Watson. Much of Dr. Sharp's scientific work has been conducted at MIT's Center for Cancer Research, which he joined in 1974.

Dr. Sharp's research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark achievement was the discovery of RNA splicing in 1977. The discovery that genes contain nonsense segments that are edited out by cells in the course of utilizing genetic information is important in understanding the genetic causes of cancer and other diseases. For this work he received the 1993 Nobel Prize in Physiology or Medicine. His lab has now turned its attention to understanding how RNA molecules act as switches to turn genes on and off (RNA interference). These newly discovered processes have revolutionized cell biology and could potentially generate a new class of therapeutics.

Dr. Sharp has received numerous awards and honorary degrees, and has served on many advisory boards for the government, academic institutions, scientific societies and companies. In addition to the Nobel Prize, his awards include the Gairdner Foundation International Award, the Albert Lasker Basic Medical Research Award, the National Medal of Science for Biological Sciences and the inaugural Double Helix Medal from Cold Spring Harbor Laboratory. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Sharp co-founded Biogen (now Biogen Idec), Alnylam Pharmaceuticals, an early-stage therapeutics company and Magen Biosciences Inc., a biotechnology company developing agents to promote the health of human skin.

 

Back to top


Lee J. Helman, M.D.
Scientific Director for Clinical Research
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD


Lee J. Helman received his M.D. from the University of Maryland School of Medicine magna cum laude in 1980 and was elected to Alpha Omega Alpha. He completed his internship and residency in internal medicine at Barnes Hospital Washington University also serving as chief resident. Dr. Helman began his fellowship training at the National Cancer Institute (NCI) in 1983, where he has remained. He did his postdoctoral training in the Molecular Genetics Section, Pediatric Branch, NCI, and became head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He became chief of the Pediatric Oncology Branch from 1997-2007, and in 2007 became scientific director for clinical research in the Center for Cancer Research, National Cancer Institute, a position he currently holds. 

Dr. Helman is a professor of pediatrics and oncology at the Johns Hopkins University. He was elected to the American Society for Clinical Investigation and the American Association of Physicians and is a founding member and past president of the Connective Tissue Oncology Society. He serves on the Board of Directors of and is a clinical advisor to The Children’s Inn at NIH and is a past member of the Board of Governors of the Clinical Center at NIH. Dr. Helman is a past member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and a past chair for its Bylaws Committee. He received the 2011 ASCO Pediatric Oncology Award and the ASCO Statesman Award. He has served on the Science Education, Publications and Clinical and Translational Research committees of the American Association of Cancer Research (AACR) and is chair of its Pediatric Oncology Task Force and has been on the Scientific Program Committee for several of its annual meetings. He serves on the Scientific Advisory Committee of Stand Up To Cancer, a scientific partner to the AACR. He is on the Scientific Advisory Committee of the Children’s Oncology Group. Dr. Helman served as an associate editor for the journal Cancer Research and Clinical Cancer Research and currently is on the editorial board of the Journal of Clinical Oncology.

Dr. Helman's laboratory currently focuses on three major themes related to the biology and treatment of pediatric sarcomas, specifically Ewing’s sarcoma, rhabdomyosarcoma and osteosarcoma: (1) determine the pathophysiologic consequences of IGF signaling; (2) identify the molecular/biochemical determinants of the biology of these sarcomas; and (3) apply preclinical laboratory findings to develop novel clinical studies for these sarcomas.

Back to top    


Jeffrey M. Lipton, M.D., Ph.D.
Chief, Hematology/Oncology and Stem Cell Transplantation
Steven and Alexandra Cohen Children’s Medical Center of New York,
New Hyde Park, NY

 

Jeffrey M. Lipton, M.D., Ph.D. is currently the chief of hematology/oncology and stem cell transplantation at the Steven and Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, NY; center head, patient-oriented research, The Feinstein Institute for Medical Research professor, Elmezzi Graduate School of Molecular Medicine, The Feinstein Institute for Medical Research; and professor of pediatrics and molecular medicine at the Hofstra North Shore – LIJ School of Medicine. He holds a B.A. from Queens College, City University of New York. He received a doctoral degree in chemistry from Syracuse University and his medical degree, magna cum laude, from Saint Louis University Medical School. He did his pediatric training at the Children’s Hospital, Boston, MA, and his pediatric hematology/oncology fellowship training at the Children’s Hospital and the Dana-Farber (née Sidney Farber) Cancer Institute in Boston. Prior to joining the Hofstra North Shore-LIJ School of Medicine he was a professor of pediatrics at the Albert Einstein College of Medicine in New York.

Dr. Lipton is the immediate past-president (2010-2012) of the American Society of Pediatric Hematology/Oncology (ASPHO) and recipient of the 2010 Saint Louis University’s School of Medicine Alumni Merit Award. Dr. Lipton’s interests focus on the rare inherited bone marrow failure syndromes. He currently directs the translational program devoted to understanding the genetics, cellular and molecular biology of Diamond Blackfan anemia (DBA) and in particular malignant predisposition and birth defects observed in patients with DBA. His lab was the first to describe Diamond Blackfan anemia as a disorder of proapoptotic erythropoiesis. He is an author of over 170 original articles, reviews and book chapters.

Back to top


Julian Adams, Ph.D.
President of Research and Development
Infinity Pharmaceuticals Inc.
Cambridge, MA

 

Julian Adams, Ph.D., is the president of research and development of Infinity Pharmaceuticals Inc. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. Prior to joining Infinity, Dr. Adams was the senior vice-president of drug discovery and development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. Earlier in his career, Dr. Adams served in various positions at LeukoSite, ProScript Inc., and Boehringer Ingelheim, where he successfully discovered the drug Viramune® for HIV.

Dr. Adams is an inventor of over 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals, and is the editor of Proteasome Inhibition in Cancer Therapy. He has received many awards, including the 2001 Ribbon of Hope Award for VELCADE® from the International Myeloma Foundation and the AACR-Bruce F. Cain Memorial Award.

Back to top

Peter C. Adamson, M.D.*
Chair, Children’s Oncology Group
Chief, Division of Clinical Pharmacology and Therapeutics
The Children's Hospital of Philadelphia
Philadelphia, PA

 

Peter C. Adamson, M.D. is chair of the Children’s Oncology Group (COG), a National Cancer Institute (NCI) supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer. He is professor of pediatrics and pharmacology at the University of Pennsylvania School of Medicine and chief of the division of clinical pharmacology and therapeutics at The Children’s Hospital of Philadelphia. Dr. Adamson is board certified in pediatric hematology/oncology and in clinical pharmacology. He is an internationally recognized leader in pediatric cancer drug development, having served until 2008 as chair of the COG’s Developmental Therapeutics Program. Prior to becoming chair of the COG, Dr. Adamson served as director for clinical and translational research at The Children’s Hospital of Philadelphia. His laboratory focuses on the clinical pharmacology of new drugs for childhood cancer.

* Dr. Adamson participated in the review of the Letters of Intent, but not the Full Proposals.

 

Back to top


Kenneth C. Anderson, M.D., Ph.D.
Kraft Family Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

 

Kenneth C. Anderson, M.D., Ph.D., is the Kraft Family professor of medicine at Harvard Medical School as well as director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke distinguished clinical research scientist and American Cancer Society clinical research professor.  After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Dr. Anderson is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011, he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Back to top


Smita Bhatia, M.D.
Chair, Division of Population Sciences
Comprehensive Cancer Center | City of Hope
Duarte, CA

 

Smita Bhatia, M.D., is the first holder of the Ruth Ziegler chair in population sciences. She also serves as the associate director for population sciences research as well as the program co-Leader for cancer control and population sciences. Dr. Bhatia established the department of population sciences at City of Hope in 2006. An internationally renowned leader in cancer survivorship research, she serves as the associate chair for the Children’s Oncology Group, coordinating survivorship research across 200 pediatric oncology institutions in the U.S. She was elected to membership in the American Society for Clinical Investigation in recognition of meritorious and outstanding contributions as a physician scientist. She is the recipient of the Frank H Oski Lectureship Award from the American Society of Pediatric Hematology Oncology to honor outstanding investigation in pediatric hematology/oncology. In 2012, she was elected to the Board of Directors for the American Society of Clinical Oncology.

Back to top
Steven J. Burakoff, M.D.
Director, The Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
New York, NY

 

Steven J. Burakoff, M.D., is currently a professor of medicine, hematology/medical oncology, professor of oncological sciences, and the director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. A native New Yorker, he graduated from Lehigh University with a Bachelor of Science degree, received his Master’s degree from Queens College, and his M.D. from Albany Medical College. Dr. Burakoff, who prior to his appointment in 2007 to Mount Sinai School of Medicine, was the Laura and Isaac Perlmutter professor at New York University School of Medicine, the director of the New York University Cancer Institute, and the director of the Skirball Institute of Biomolecular Medicine at the New York University School of Medicine from 2000 to 2007. Prior to joining the New York University School of Medicine, in 2000, he was chair of pediatric oncology at the Dana-Farber Cancer Institute and the Margaret M. Dyson professor of pediatrics at the Harvard Medical School, and also received an Honorary Master’s of Science degree from Harvard University. He was the recipient of the first Harvard Medical School Excellence in Mentoring Award.  He was also the Ted Williams senior investigator at the Dana-Farber Cancer Institute, and he also served as a member of the Board of Trustees of the Dana-Farber Cancer Institute.

Dr. Burakoff serves as a member of the External Advisory Committee at the Cold Spring Harbor Laboratory Cancer Center and St. Jude Cancer Center. He is also on the Board of Directors of the Damon Runyon Cancer Research Foundation, as well as the Advisory Boards of the Starr Cancer Consortium and the Melanoma Research Alliance. Dr. Burakoff holds memberships in many professional societies and organizations, including: Alpha Omega Alpha, the American Society of Clinical Investigation, and the Association of American Physicians, and the American Association of Immunologist where he served as secretary-treasurer. He has been an editor and associate editor for numerous journals and author of more than 300 publications in peer-reviewed journals. In 2009, Dr. Burakoff received the American Association of Immunologists Lifetime Achievement Award. Also in 2009, Dr. Burakoff received the Lillian and Henry M. Stratton Professor of Cancer Medicine, an endowed professorship from the Mount Sinai School of Medicine.

Dr. Burakoff’s recent research interest is the study of signaling cascades that govern T-cell activation and regulate their functions, focusing research on signaling molecules and pathways that negatively regulate the effector functions of both CD4+ and CD8+ T cells. Finally, given their long-standing interest in CD4 function, Dr. Burakoff’s laboratory has recently turned its attention to studying the interaction of the HIV Nef protein with CD4.

Back to top


Alan D. D'Andrea, M.D.
The Fuller-American Cancer Society Professor
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

 

A graduate of Harvard College, Dr. Alan D. D’Andrea received his M.D. from Harvard Medical School in 1983. He completed his residency in pediatrics at Children's Hospital of Philadelphia, and a fellowship in pediatric hematology-oncology at DFCI and Children's Hospital, Boston. Dr. D’Andrea also completed a research fellowship at the Whitehead Institute of Biomedical Research at MIT where he cloned the receptor for erythropoietin while working in the laboratory of Harvey Lodish. Dr. D’Andrea joined the staff at DFCI in 1990. His research is focused on the molecular cause of leukemia. He also investigates the pathogenesis of Fanconi anemia, a human genetic disease characterized by bone marrow failure and AML in children.    

Dr. D’Andrea is internationally known for his research in the area of DNA damage and DNA repair. He is currently the Fuller-American Cancer Society professor of radiation oncology at Harvard Medical School and the chief of the division of genomic stability and DNA repair at Dana-Farber Cancer Institute. A recipient of numerous academic awards, Dr. D’Andrea is a former Stohlman Scholar of the Leukemia and Lymphoma Society, and has previously served on its Medical and Scientific Advisory Board. He is currently chairman-elect of the Career Development Selection Committee of the LLS, and chairman of the NIH Molecular and Cellular Hematology Study Section. Dr. D’Andrea is a distinguished clinical investigator of the Doris Duke Charitable Trust, and a Fellow of the American Association for the Advancement of Science. He is also the recipient of the 2001 E. Mead Johnson Award, the highest award in pediatric research, and the 2012 G.H.A. Clowes Memorial Award from the American Association for Cancer Research.

Back to top


Stephen H. Friend, M.D. Ph.D.
President and Co-Founder
Sage Bionetworks
Seattle, WA

 

Stephen H. Friend, M.D., Ph.D., is an authority in the field of cancer biology and a leader in efforts to make large-scale, data-intensive biology broadly accessible to the entire research community.  He has more than a decade of experience using large datasets and integrating system biology approaches to complex diseases. This includes work pioneering the field of the genetics of gene expression. Dr. Friend is the president of Sage Bionetworks and director of the new Sage Bionetworks Center for Cancer Systems Biology where he actively leads an interdisciplinary team of network, systems and computational biologists. Sage Bionetworks’ mission is to develop predictive disease models based on globally coherent datasets built from clinical data and multiple layers of genomic data using Bayesian and co-expression approaches.

Dr. Friend has been a senior advisor to the NCI and several biotech companies, a trustee of the AACR and recently was made an AAAS Fellow. After receiving a Ph.D. in biophysics, Dr. Friend did his clinical training at Children’s Hospital of Philadelphia and the Dana-Farber Cancer Research Institute in Boston. He had lab training in the Weinberg lab at the Whitehead Institute where he led the team that cloned the first tumor suppressor gene p53 and characterized its role in controlling the cell cycle. Dr. Friend next joined Dr. Leland Hartwell at the FHCRC to establish the Seattle Project and explore how model organisms could provide insights into cancer and chemotherapeutic responses. In 1997, they co-founded Rosetta Inpharmatics where they showed that expression patterns could provide detailed functional snapshots linking yeast and man. After Rosetta was bought by Merck & Co. Inc. in 2001, Dr. Friend was recruited to become a senior vice-president at Merck, head its molecular profiling effort and form a new oncology unit which placed seven new chemical entities into clinical trials in seven years. Recognizing that genetic datasets were too fragmented and siloed and data and model sharing was inadequate, he left Merck in 2009 to form Sage Bionetworks, a non-profit foundation with Dr. Eric Schadt. Dr. Friend is also co-leader of the Arch2POCM initiative that is building an open, pre-competitive research infrastructure for collaborative preclinical and proof of concept in man drug development.  

Back to top


Michael B. Kastan, M.D., Ph.D.
Executive Director, Duke Cancer Institute
Duke University School of Medicine
Durham, NC

 

Michael B. Kastan, M.D., Ph.D., is the executive director of the Duke Cancer Institute. He earned M.D. and Ph.D. degrees from the Washington University School of Medicine and did his clinical training in pediatrics and pediatric hematology-oncology at Johns Hopkins. He was a professor of oncology, pediatrics, and molecular biology at Johns Hopkins prior to becoming chair of the hematology-oncology department and later cancer center director at St. Jude Children’s Research Hospital, before moving to Duke earlier this year. He is a pediatric oncologist and a cancer biologist; his laboratory research concentrates on DNA damage and repair, tumor suppressor genes, and causes of cancer related to genetic predisposition and environmental exposures. His discoveries have made a major impact on our understanding of both how cancers develop and how they respond to chemotherapy and radiation therapy and his publications reporting the role of p53 and ATM in DNA damage signaling are among the most highly cited publications in the biomedical literature of the past two decades.

Dr. Kastan has received numerous honors for his highly cited work, including election to the National Academy of Sciences’ Institute of Medicine and receiving the 47th annual AACR-G.H.A. Clowes Memorial Award for outstanding contributions to basic cancer research. He has served as chairman of the Board of Scientific Counselors of the National Cancer Institute and on the Board of Directors of the American Association for Cancer Research. He is currently editor-in-chief of the journal Molecular Cancer Research and editor of the textbook Clinical Oncology.

Back to top


Paul S. Meltzer, M.D., Ph.D.
Head, Molecular Genetics Section
Branch Chief
National Cancer Institute
National Institutes of Health
Bethesda, MD

Paul S. Meltzer, M.D., Ph.D., has been chief of genetic branch, Center for Cancer Research, National Cancer Institute since 2006. He leads the Molecular Genetics Group. The goal of the Molecular Genetics Section is to characterize the disturbances of genome function responsible for cancer development and to utilize this information to identify genes and pathways responsible for tumor development. The central importance of somatically acquired genetic and epigenetic alterations in the tumor genome is now well established. His work uses genome technologies to attack these problems in the context of specific diseases. Dr. Meltzer received his A.B in biology from Dartmouth College in 1967. He received his Ph.D. in biochemistry/developmental biology in 1972 from California Institute of Technology, and his M.D. from the University of Tennessee in 1980. He was a postdoctoral fellow in the Department of Genetics at the University of Cambridge from 1972-1974. This was followed by a residency in pediatrics at the Arizona Health Sciences Center in Tucson, Arizona, from July 1983-1985. He was a fellow in pediatric hematology-oncology at the Arizona Health Sciences Center, in Tucson, Arizona, from 1983-1985.  Before his current position, Dr. Meltzer was a research assistant professor of pediatrics at the Arizona Health Sciences Center from July 1985- June, 1987. He was assistant professor of pediatrics at the University of Arizona, July 1987 –July 1990. He then became assistant professor of pediatrics and radiation oncology at the University of Michigan from August 1990-1993. In 1993, he was associate professor of pediatrics and radiation oncology at the University of Michigan. In 1993, he became the chief of the molecular genetics section, Cancer Genetics Branch, National Human Genome Research Institute at National Institutes of Health and he served in that capacity until 2006, when he became chief of genetics branch, Center for Cancer Research, National Cancer Institute.

Back to top


Geoffrey Corb
Senior Director, Enterprise Applications
Johns Hopkins University and Johns Hopkins Health System
Baltimore, MD

 

Geof Corb is the senior information technology leader responsible for enterprise applications for the Johns Hopkins University and the Johns Hopkins Health System. Reporting to the CIO, Geof manages the business systems for the nearly $10B Johns Hopkins enterprise, in addition to a portfolio of technologies and related services that support the university's academic and research missions. Geof earned a B.S. in computer science in 1997 and an MBA in 2012, both from Johns Hopkins. Pediatric cancers have had a devastating effect on the Corb family. In June 2006, at 3 months of age, Geof's infant son Michael was diagnosed with mixed-lineage leukemia and was treated by Dr. Robert Arceci at the Johns Hopkins Hospital. Michael received a bone marrow transplant in October of that year and died as a result of graft-versus-host disease and related complications in December when he was only nine months old. Michael was named after his maternal uncle who was diagnosed with a glioblastoma multiforme when he was 14 and died two years later. Geof, his wife Jenn, and children Alyssa (9), Jonathan (5), and Sarah (2) continue to celebrate the memory of their Michaels by supporting pediatric cancer research efforts. Alyssa has now participated in Swim Across America for two consecutive years, raising almost $14,000 to support the Sidney Kimmel Cancer Center at Johns Hopkins. Geof is a family advisor on the Family Advisory Committee at the Johns Hopkins Hospital and will soon be a bone marrow donor, having been identified as a match for an unrelated patient in need. 

Back to top


Nancy F. Goodman
Founder and Executive Director
Kids v. Cancer
Washington D.C.

 

Nancy F. Goodman is a leading pediatric cancer advocate and is the founder and executive director of Kids v Cancer, whose mission is to promote pediatric cancer research by identifying structural impediments at key junctures in the research process – new drugs, tissue donation and access to funding – and developing strategies to address them. Through Kids v Cancer, Ms. Goodman successfully authored and championed a federal law, the Creating Hope Act, Section 908 of the FDA Safety and Innovation Act, which creates a market-based incentive to spur pediatric cancer drug development. The Creating Hope Act went into effect on October 1, 2013. Nancy Goodman and Kids v Cancer are now working with the FDA, researchers and drug companies to ensure its full and effective implementation. 

In addition, Ms. Goodman is working with the FDA  in other policy areas to help strengthen pediatric drug development. She is an active member of the patient representative and consultant program at the FDA. Ms. Goodman has started an autopsy tissue donation program for pediatric brain cancers which has already had significant impact on scientific discoveries. Through Kids v Cancer, she has raised the profile of pediatric cancer issues by having September declared to be National Childhood Cancer Awareness Month for each of the past three years. Ms. Goodman founded Kids v Cancer in 2009 in response to the death of her ten-year-old son, Jacob, from medulloblastoma, a pediatric brain cancer. She received a BA from the University of Pennsylvania, a masters in public policy from Harvard  Kennedy School of Government and a J.D. from the University of Chicago Law School.   

 

Back to top